Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials
Wei Zhang, Li-Jin Feng, Fei Teng, Yanhong Li, Xi Zhang, Yu-Ge Ran
Abstract
: Treatment with newly approved VEGFR-TKIs significantly increases the risk of developing proteinuria events in cancer patients, especially for patients treated with lenvatinib.
Topics & Concepts
MedicineRandomized controlled trialIncidence (geometry)Meta-analysisProteinuriaVascular endothelial growth factorInternal medicineOncologyVEGF receptorsKidneyOpticsPhysicsAngiogenesis and VEGF in CancerGastric Cancer Management and OutcomesRenal cell carcinoma treatment